Express News | Benchmark Reiterates Speculative Buy on Unicycive Therapeutics, Maintains $3 Price Target
Moomoo 24/7Apr 15 11:00 ET
Buy Rating Affirmed for Unicycive Therapeutics on Strong Trial Progress and Financial Positioning
TipRanksApr 11 15:05 ET
Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
LOS ALTOS, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company or
GlobeNewswireApr 10 07:03 ET
Express News | Unicycive Therapeutics Shares Are Trading Higher After Piper Sandler Initiated Coverage on the Stock With an Overweight Rating and a Price Target of $9
Moomoo 24/7Apr 4 07:53 ET
Unicycive Therapeutics Initiated at Overweight by Piper Sandler
Unicycive Therapeutics Initiated at Overweight by Piper Sandler
Dow JonesApr 4 07:13 ET
Express News | Piper Sandler Initiates Coverage On Unicycive Therapeutics With Overweight Rating, Announces Price Target of $9
Moomoo 24/7Apr 4 07:03 ET
Unicycive Therapeutics: A Strong Buy on OLC's Potential to Revolutionize Hyperphosphatemia Treatment in CKD
TipRanksApr 4 05:05 ET
Express News | CORRECTION: On Friday, Unicycive Therapeutics Reported Q4 EPS Of $(0.22), Which Missed $(0.17) Estimate
Moomoo 24/7Apr 1 07:04 ET
Unicycive Therapeutics Q4 EPS $(0.35) Misses $(0.17) Estimate
Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.17) by 105.88 percent. This is a 31.37 percent increase over loss
BenzingaMar 29 00:53 ET
Unicycive Therapeutics GAAP EPS of -$1.28, Revenue of $0.7M
Seeking AlphaMar 28 17:03 ET
Unicycive Therapeutics to Be Featured in Multiple Presentations at the Upcoming European Renal Association Congress
Unicycive Therapeutics, Inc. (Nasdaq: UNCY) today announced that multiple presentations will be delivered on the Company's product candidates, oxylanthanum carbonate (OLC) and UNI-494, at the 61st European Renal Association (ERA) Congress taking place May 23-26, 2024, in Stockholm, Sweden.
GlobeNewswireMar 25 07:03 ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersAptorum Gr (NASDAQ:APM) shares moved upwards by 47.1% to $6.37 during Thursday's pre-market session. The company's market cap stands at $33.0 million. Nuvectis Pharma (NASDAQ:NVCT) stock moved
BenzingaMar 14 09:06 ET
Express News | Unicycive Therapeutics Shares Are Trading Higher. The Company Announced a $50 Million Private Placement
Moomoo 24/7Mar 14 08:01 ET
Express News | Unicycive Therapeutics Announced It Has Entered Into A Securities Purchase Agreement With Certain Healthcare-focused Institutional Investors For The Sale Of 50,000 Shares Of Its Series B Convertible Preferred Stock At An Offering Price Of $1,000 Per Share
Moomoo 24/7Mar 14 07:10 ET
Unicycive Announces $50 Million Private Placement
LOS ALTOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY) (the "Company" or "Unicycive"), a clinical-stage biotechnology company developing therapies for patients with kidney
GlobeNewswireMar 14 07:03 ET
Unicycive Reports Progress in Kidney Injury Treatment Trial
Unicycive Therapeutics, Inc. (NASDAQ: UNCY), a biotech firm focusing on kidney disease therapies, has reported successful completion of the single ascending dose (SAD) portion of its ongoing Phase 1 clinical trial for UNI-494, a drug candidate aimed at preventing delayed graft function (DGF) after kidney transplantation.
Investing.com Mar 13 07:48 ET
Noble Financial Keeps Their Buy Rating on Unicycive Therapeutics (UNCY)
TipRanksMar 11 07:55 ET
Unicycive Therapeutics Completes Patient Enrollment in Pivotal Trial for Investigational Therapy for Hyperphosphatemia
Unicycive Therapeutics (UNCY) said Thursday it has completed patient enrollment in a pivotal clinical trial for Oxylanthanum Carbonate for the potential treatment of hyperphosphatemia in patients with
MT NewswiresMar 8 06:26 ET
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersAinos (NASDAQ:AIMD) shares moved upwards by 100.0% to $2.24 during Thursday's after-market session. The market value of their outstanding shares is at $10.4 million. Talphera (NASDAQ:TLPH) stoc
BenzingaMar 7 16:31 ET
Express News | Unicycive Therapeutics Completes Enrollment In Pivotal Clinical Trial For Oxylanthanum Carbonate
Moomoo 24/7Mar 7 16:12 ET
No Data
No Data